Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

Core Insights - INmune Bio, Inc. has published an overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, particularly focusing on its CORDStrom™ platform, in the journal Cytotherapy [1][2] Group 1: Research and Development - The article reviews current knowledge and identifies critical gaps in MSC therapies to enhance their development, including topics like systemic delivery and in vivo persistence [2] - CORDStrom™ is initially being developed for recessive dystrophic epidermolysis bullosa (RDEB), with plans to file a Biologics License Application (BLA) and Marketing Authorization Application (MAA) in 2026 [3] - The publication provides important scientific background for the future development of the CORDStrom™ platform, which may significantly impact various indications such as inflammation and wound healing [3] Group 2: CORDStrom™ Platform - CORDStrom™ is a patent-pending cell medicine made from aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) designed for injection or infusion [4] - The platform utilizes proprietary techniques for screening, pooling, and expanding hucMSCs, aiming to create consistent, scalable, and affordable cellular medicines for complex diseases [4] - CORDStrom™ products are designed to be indication-specific, optimizing characteristics for anti-inflammatory and immunomodulatory effects [4] Group 3: Company Overview - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments targeting innate immune dysfunction [5] - The company's pipeline includes CORDStrom™, DN-TNF Platform (XPro™/XPro1595) for neuroinflammatory conditions, and INKMune™ for cancer treatment [7]